Wyeth - Biotech Market Share Report

Wyeth market share report featuring Enbrel

Company: Wyeth
2007 Sales:
$2.2 billion
Market share: 3%
CAGR: 38.4%

What they have: Wyeth's top-selling biologic is Enbrel, which it markets with Amgen. The monoclonal antibody is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and chronic moderate to severe plaque psoriasis.

What to look for: Bapineuzumab--currently in Phase III development--is a humanized monoclonal antibody being investigated for the treatment of Alzheimer's disease and possibly glaucoma.

Wyeth - Biotech Market Share Report
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.